BioCareSD, a specialty distributor of life-saving therapies, is proud to announce the addition of LEQEMBI to their diverse portfolio of specialty therapeutics. LEQEMBI was recently approved by the U.S. Food and Drug Administration (FDA) under the Accelerated Approval Pathway for the treatment of moderate-to-severe Alzheimer’s disease. The innovative new therapy developed by Biogen and Eisai has shown in studies that it may slow cognitive decline in early-stage Alzheimer’s disease. With this recent acquisition, BioCareSD hopes to expand the reach of this groundbreaking therapy for those suffering from this devastating condition.
“LEQEMBI is an important advancement in the ongoing fight to effectively treat Alzheimer’s disease,” said Jeff Beck, BioCareSD’s Chief Development Officer. “The team at BioCareSD is thrilled to be able to support its partners in providing patients with access to this new therapy.”
This addition further reinforces BioCareSD’s commitment to leading the specialty distribution industry by offering best-in-class customer service and a unique distribution network that ensures the highest quality patient care.
Over the last four decades, BioCareSD has built a trusted track record with manufacturers and healthcare providers in ensuring life-sustaining therapies are delivered to patients with ultra-rare, rare, and orphan diseases where and when they are needed. These strong relationships continue to elevate BioCareSD’s industry standing by providing patients with increased access to specialty therapeutics.
LEQEMBI is now available through BioCareSD’s extremely fast and reliable specialty distribution network. Dedicated to ensuring that life-sustaining therapies are delivered where and when they are needed, BioCareSD will continue to diversify its offerings to meet customer demand. For more information, please visit www.biocaresd.com.